Update on Inclusion Body Myositis.

Area of Science:

• Neurology
• Immunology
• Pathophysiology

Background:

• Sporadic inclusion body myositis (sIBM) is the most prevalent acquired muscle disease in individuals over 50.
• The underlying pathogenesis of sIBM remains incompletely understood, necessitating further research.

Purpose of the Study:

• To review the current knowledge on sporadic inclusion body myositis (sIBM).
• To provide an updated understanding of sIBM pathophysiology and management strategies.

Main Methods:

• Review of existing literature and research findings on sIBM.
• Analysis of evidence supporting both inflammatory and degenerative pathophysiological mechanisms.
• Examination of recent therapeutic trial focuses.

Main Results:

• Evidence initially suggested an inflammatory basis for sIBM, including inflammatory infiltrates and cytokine responses.
• Refractoriness to immunotherapy points towards a degenerative pathophysiology.
• Impaired protein homeostasis, endoplasmic reticulum stress, and mitochondrial dysfunction are key findings supporting degeneration.
• Recent trials increasingly target degenerative processes and muscle growth over inflammation.

Conclusions:

• Growing evidence suggests degeneration is the primary process in sIBM, explaining its resistance to treatment.
• A deeper understanding of sIBM pathogenesis is essential for advancing effective therapeutic interventions.